GET DAILY SIGNALSCompugen (CGEN) Reports Q3 2026 Results With Narrowing Losses and Steady Clinical Progress
Key Takeaways
- Compugen reported a third quarter 2026 net loss of roughly $5.8 million, or $0.06 per share, narrowing from a $7.0 million loss, or $0.07 per share, a year earlier.
- The loss per share beat consensus estimates of about $0.08, while revenue of approximately $3.8 million roughly doubled year-over-year and came in ahead of expectations.
- Management said the MAIA-Ovarian trial of COM701 is now fully enrolled, with data still expected by the end of the first quarter of 2027.
- The company held about $117.5 million in cash and marketable securities as of September 30, 2026, with a cash runway expected to fund operations into 2029.
- AstraZeneca's Phase III readout for rilvegostomig is now anticipated in the second half of 2027, positioning 2027 as a data-rich year.
Why These Earnings Matter
Compugen is a clinical-stage immuno-oncology company that relies on its AI-powered discovery engine to identify novel cancer drug targets. With no commercialized products yet, its financial results are shaped mainly by partnership payments rather than steady sales. That means quarterly updates matter less for bottom-line profits and more for balance-sheet health and clinical execution. Investors look for signals on trial progress, upcoming milestones, and how long the cash will last. With partnered programs from AstraZeneca and Gilead potentially worth more than $1 billion in future milestones and royalties, the third quarter 2026 results gave a useful update on how those catalysts are progressing and whether the company has enough capital to reach important data readouts.
The Numbers in Detail
For the third quarter ended September 30, 2026, Compugen reported revenue of approximately $3.8 million, up from roughly $1.9 million in the prior-year period. This reflected recognition of portions of the upfront payment and the investigational new drug milestone payment under its Gilead license agreement. Research and development expenses were approximately $5.8 million, essentially flat year-over-year, while general and administrative expenses rose modestly to about $2.3 million from $2.2 million.
The company posted a net loss of roughly $5.8 million, or $0.06 per basic and diluted share, compared with a net loss of about $7.0 million, or $0.07 per share, a year earlier. The result beat consensus estimates of a roughly $0.08 per-share loss, and revenue also landed above analyst expectations. As of September 30, 2026, cash, cash equivalents, short-term bank deposits, and marketable securities totaled approximately $117.5 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the report, investor attention was focused less on the bottom line than on clinical catalysts. The confirmation that the MAIA-Ovarian trial of COM701 — a potential first-in-class anti-PVRIG antibody — is fully enrolled was a central positive, keeping the first quarter 2027 data readout on track. The disclosure that AstraZeneca's Phase III ARTEMIDE-Biliary01 readout for rilvegostomig is now expected in the second half of 2027 also shaped sentiment, extending the timeline for a key partnered catalyst. The modest earnings and revenue beats offered limited financial significance given the company's pre-revenue status, but the steady cash position and disciplined spending were viewed as supportive. As a clinical-stage biotech, Compugen stock remains sensitive to trial outcomes and partner-driven news rather than quarterly profit fluctuations.
Forward Outlook and Key Factors to Monitor
Compugen has positioned 2027 as a pivotal, data-rich year. The most closely watched catalyst is the MAIA-Ovarian readout, expected by the end of the first quarter of 2027. This randomized, placebo-controlled trial evaluates COM701 as maintenance therapy in platinum-sensitive ovarian cancer, a setting with significant unmet need. Investors will be watching whether COM701 can demonstrate a meaningful clinical signal.
On the partnered side, AstraZeneca's rilvegostomig — a PD-1/TIGIT bispecific antibody — is advancing across multiple Phase III trials, with high-level results from ARTEMIDE-Biliary01 now anticipated in the second half of 2027. Compugen remains eligible for up to $195 million in regulatory and commercial milestones plus tiered royalties tied to this asset.
Finally, the Gilead-partnered GS-0321, a potential first-in-class anti-IL-18 binding protein antibody, continues its Phase I dose-escalation study. Combined with the newly introduced UnigenX discovery expansion, these programs give Compugen multiple avenues for future value. Key risks to monitor include potential trial delays, partner-driven disclosure timing, and the inherently lumpy nature of milestone-based revenue.
My Experience With Tickeron’s AI Screener
In my own research process, I often rely on Tickeron’s AI Screener to quickly filter for stocks with similar profiles or technical setups. It helps surface relevant ideas based on fundamentals, patterns, and AI signals without spending hours on manual work, which keeps my analysis more focused and efficient when tracking names like Compugen.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGEN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CGEN turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 46 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CGEN's RSI Oscillator exited the oversold zone, 34 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where CGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CGEN as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 187 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for CGEN moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (3.498). P/E Ratio (5.158) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are My SEP IRA Investment Options?
What is the Falling Wedge (Bullish) Pattern?
Analyzing Bank of America (BAC) Stock Performance and Market Trends in May 2025
S&P 500, Meet Your Match: Tickeron's Robot Leads the Way to Market Success!
FAQ: How can I make money on Tickeron aside from trading the signals from Tickeron products?
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement